Retatrutide 48 mg is a research vial size of an investigational triple agonist. Learn how it's reconstituted, studied, and why it's not FDA-approved.
Retatrutide 48 mg is a specific vial size containing 48 milligrams of lyophilized retatrutide powder, sold strictly for laboratory research. It is not a single human dose, and retatrutide itself is an investigational triple hormone receptor agonist that has not been approved by the FDA. Researchers reconstitute the powder with bacteriostatic water to prepare solutions for in vitro and animal studies.
What Is Retatrutide 48 mg?
Retatrutide is a synthetic peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. This triple mechanism is being studied for metabolic conditions such as obesity and type 2 diabetes. The "48 mg" figure refers to the total amount of peptide in a single vial, not a recommended dose.
These vials are marketed to research institutions and compounding labs. They are not manufactured for human injection, and no regulatory agency has approved retatrutide for any medical use. Spanish-speaking researchers sometimes search retatrutide que es to find a basic definition of the compound.
How to Reconstitute a Retatrutide 48 mg Vial
Reconstitution is the process of adding a liquid solvent to the lyophilized powder. Bacteriostatic water is the most common choice because it inhibits bacterial growth. The concentration you get depends on how much water you add.
- Clean the vial stopper with an alcohol swab.
- Draw the desired volume of bacteriostatic water into a syringe.
- Inject the water slowly against the vial wall to avoid foaming.
- Gently swirl the vial until the powder dissolves completely. Do not shake.
- Store the reconstituted solution according to the supplier's instructions, typically refrigerated.
For a 48 mg vial, here is how different water volumes affect concentration:
| Bacteriostatic Water Added | Final Concentration | Volume per 1 mg |
|---|---|---|
| 2.4 mL | 20 mg/mL | 0.05 mL |
| 4.8 mL | 10 mg/mL | 0.10 mL |
| 9.6 mL | 5 mg/mL | 0.20 mL |
| 12 mL | 4 mg/mL | 0.25 mL |
These calculations are for research use only. Never assume a 48 mg vial equals a 48 mg human dose.
Retatrutide Dosage in Clinical Studies
In published phase 2 trials, retatrutide dosage ranged from 1 mg to 12 mg administered once weekly by subcutaneous injection. Doses were titrated upward over several weeks to reduce gastrointestinal side effects. A 48 mg vial could theoretically supply multiple weekly doses at these levels, but human dosing must only occur under medical supervision.
As for how long does retatrutide take to work, trial data suggest that measurable weight loss begins within 4 to 8 weeks. Maximum effects typically appear after 24 to 48 weeks of consistent treatment. Individual responses vary widely based on dose, baseline health, and adherence.
Researchers often ask about retatrutide brand name, but there is no official brand name because the drug remains investigational. If approved in the future, it would receive a proprietary name from the manufacturer.
Retatrutide 48 mg vs Other Research Peptides
Retatrutide is one of several incretin-based peptides studied for metabolic health. Its triple agonist action makes it distinct from dual agonists like tirzepatide and single agonists like semaglutide. The table below compares common research compounds.
| Compound | Receptor Targets | Typical Research Vial Sizes |
|---|---|---|
| Retatrutide | GLP-1, GIP, glucagon | 5 mg, 10 mg, 20 mg, 48 mg |
| Tirzepatide | GLP-1, GIP | 5 mg, 10 mg, 15 mg, 30 mg |
| Cagrilintide | Amylin | 5 mg, 10 mg |
| Survodutide | GLP-1, glucagon | 5 mg, 10 mg |
When scientists compare cagrilintide vs retatrutide vs tirzepatide, they focus on differences in receptor activity and side effect profiles. Each compound targets a different combination of gut hormones, which may explain variations in efficacy and tolerability observed in early trials.
Safety and Legal Status of Retatrutide 48 mg
Retatrutide is not FDA-approved for human use in the United States. The 48 mg vial is sold as a research chemical and is not subject to the same quality standards as prescription drugs. Injecting research peptides into humans can cause serious harm, including allergic reactions, infections, and organ toxicity.
Common side effects reported in clinical trials include nausea, vomiting, diarrhea, and constipation. More serious risks may include pancreatitis and gallbladder disease. Anyone considering retatrutide for weight loss should consult a licensed healthcare professional and only use FDA-approved treatments.
Retatrutide 48 mg is a laboratory quantity, not a therapeutic dose. Human use of unapproved research peptides is dangerous and illegal in many jurisdictions.
Key Takeaways for Researchers
- Retatrutide 48 mg describes a vial containing 48 milligrams of lyophilized peptide powder.
- Reconstitution with bacteriostatic water changes concentration; a 4.8 mL addition yields 10 mg/mL.
- Clinical trial doses ranged from 1 mg to 12 mg weekly, but those doses are not instructions for self-administration.
- Retatrutide has no FDA approval and no official brand name as of 2025.
- Always follow institutional safety guidelines and consult a healthcare provider for any human health questions.
Frequently Asked Questions
What is retatrutide 48 mg used for?
Retatrutide 48 mg vials are sold for laboratory research only, not for human consumption. Scientists use the powder to prepare solutions for in vitro and animal studies of metabolic pathways. It is not a treatment for obesity or diabetes.
Is retatrutide FDA-approved?
No, retatrutide is not FDA-approved for any human use. It remains an investigational drug in clinical trials. Any 48 mg vial sold online is a research chemical and has not been evaluated by the FDA for safety or effectiveness.
How much bacteriostatic water do I add to a 48 mg retatrutide vial?
The amount depends on your desired concentration. Adding 4.8 mL of bacteriostatic water to a 48 mg vial yields a 10 mg/mL solution. Adding 9.6 mL yields 5 mg/mL. Always follow your research protocol and never use the solution in humans.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.